Lumos is a high-risk but potentially asymmetric medtech scale-up, with FDA-cleared, CLIA-waived FebriDx transforming a niche diagnostics developer into a U.S. outpatient commercialization story.
Overview
Lumos Diagnostics is a commercial-stage point-of-care diagnostics company with two reinforcing engines: proprietary rapid tests and contract development/manufacturing services. Its flagship FebriDx test rapidly distinguishes bacterial from viral/non-bacterial acute respiratory infections, supporting antibiotic stewardship and clinical workflow efficiency. The U.S. is the core market, now unlocked by FDA clearance and CLIA waiver status. Revenue comes from product sales, commercial services, and IP licensing, with Hologic, PHASE Scientific, and Micro-Pak relationships providing validation, scale-up pathways, and recurring commercial potential.